ACADEMIA

Academic Societies Warn against Hoarding Meropenem as Supply Crunch Intensifies

By Tatsuya Otsuka, Sakura Kono, and Kazuhiro Chiboshi November 21, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Four Japanese academic societies issued a joint statement on November 18 calling for medical institutions to place rationalized orders for the antibiotic meropenem and avoid excessive purchases amid continued shortages of its supplies. Jiho has learned that the shipments of…

To read the full story

Towa Hopes to Resume Meropenem 0.5 g Shipment in March
December 27, 2022
All Companies Curbing Shipments of Meropenem, Top-Priority Drug Requiring Stable Supplies
August 23, 2022

ACADEMIA

Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026
Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…